B2M and lung carcinoma: Irreversible alterations such as B2M mutations and HLA class I loss of heterozygosity (LOH) are frequently observed in melanoma, lung cancer, and microsatellite instability–high colorectal cancer, particularly in tumours that relapse after immune checkpoint blockade.81, 82